Results 51 to 60 of about 155 (115)

Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression

Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.
This study presents post‐hoc analysis of sociodemographic and clinical features of ketamine nonresponders among treatment‐resistant bipolar depression patients. Non‐response to ketamine is associated with a greater psychiatric comorbidity burden and more frequent history of benzodiazepine use. ABSTRACT Objectives Ketamine is a prototypical rapid‐acting
Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek, Michał Pastuszak, Krzysztof Pastuszak, Aleksander Kwaśny   +5 more
wiley   +1 more source

Esketamine in Treatment-Resistant Depression and Suicidal Ideation: A Systematic Review

Journal of Education, Health and Sport
Background. Major depressive disorder affects 20% of the global population, with treatment-resistant depression in 10-30% of cases. Patients with acute suicidal ideation need immediate intervention, yet conventional antidepressants require weeks to work.
Natalia Dudziak, Zuzanna Drozd, Bartosz Niemiec, Szymon Piosik, Bruno Olesiński, Łukasz Piasecki, Zuzanna Guzowicz, Monika Kamińska, Patrycja Gągałka   +8 more
doaj   +1 more source

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression

Brain Sciences, 2023
Psychotic treatment-resistant depression is a complex and challenging manifestation of mood disorders in the clinical setting. Psychotic depression is a subtype of major depressive disorder characterized by mood-consistent hallucinations and/or delusions.
Maria Gałuszko-Węgielnik, Zuzanna Chmielewska, Katarzyna Jakuszkowiak-Wojten, Mariusz S. Wiglusz, Wiesław J. Cubała   +4 more
doaj   +1 more source

Dextromethorphan Bupropion Combination Tablet Suicide Attempt by Overdose: A Case Report

Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.
Dextromethorphan and bupropion in combination are approved to treat major depressive disorders in adults. This case report describes a patient with a history of treatment‐resistant depression who presented to the emergency department after overdosing on approximately 30 tablets of dextromethorphan‐bupropion 45–105 mg in a suicide attempt.
Daniel Greer, Justina Girgis, John Kashani, Jennifer Atherton   +3 more
wiley   +1 more source

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality

BMC Psychiatry, 2023
Background Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.
Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, Stephane Borentain, Shien Guo, Maju Mathews, Joana Anjo, Abigail I. Nash, Marguerite O’Hara, Carla M. Canuso   +9 more
doaj   +1 more source

Efficacy of Midazolam in Outpatient Pediatric Dentistry: A Systematic Review

Special Care in Dentistry, Volume 45, Issue 5, September/October 2025.
ABSTRACT Aims The aim of this systematic review was to analyze the efficacy, advantages and adverse effects of midazolam in outpatient pediatric dentistry. Methods This review was carried out in accordance with the PRISMA criteria. A systematic electronic search was conducted through MEDLINE/PubMed, Scopus, and the Cochrane Library databases up to ...
Judit Rabassa‐Blanco, Pau Cahuana‐Bartra, Yndira González‐Chópite, María Dolores Rocha‐Eiroa, Albert Ramírez‐Rámiz, Elias Isaack Mashala, Lluís Brunet‐Llobet, Jaume Miranda‐Rius   +7 more
wiley   +1 more source

Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT In the 1950s–60s, serotonergic psychedelic drugs were studied as potential adjuvants to psychotherapy to treat addiction and alcoholism. However, starting in the 70s, preclinical and clinical studies on psychedelics stopped for decades because legislation controlled its recreational use, citing their hallucinogenic and psychotomimetic effects,
Makiath Adebo, Mathilda Bonnet, Ons Laouej, Celine Defaix, Josephine C. McGowan, Florence Butlen‐Ducuing, Denis J. David, Erwan Poupon, Laurent Tritschler, Alain M. Gardier   +9 more
wiley   +1 more source

Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk

Human Psychopharmacology: Clinical and Experimental, Volume 40, Issue 4, July 2025.
ABSTRACT Objective Treatment‐resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real‐world outpatient setting.
Maurizio Pompili, Maria Anna Trocchia, Ludovica Longhini, Eva Dispenza, Cristina Di Legge, Salvatore Sarubbi, Denise Erbuto, Isabella Berardelli   +7 more
wiley   +1 more source

Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression

Neuropsychiatric Disease and Treatment, 2022
Joachim Morrens,1 Maju Mathews,2 Vanina Popova,1 Stephane Borentain,2 Benoit Rive,3 Beatriz Gonzalez Martin Moro,4 Carol Jamieson,5 Qiaoyi Zhang2 1Janssen Research & Development, Beerse, Belgium; 2Janssen Global Services, LLC, Titusville, NJ, USA ...
Morrens J, Mathews M, Popova V, Borentain S, Rive B, Gonzalez Martin Moro B, Jamieson C, Zhang Q   +7 more
doaj  

The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases

MedComm, Volume 6, Issue 6, June 2025.
Τhe BBB restricts CNS drug delivery. NBDD bypasses the BBB via olfactory/trigeminal routes, enabling CNS delivery of therapeutic (small molecules, biologics, nucleic acids) for neurodegenerative/psychiatric disorders and brain tumors using advanced NBDD delivery systems (e.g nanocarriers) to enhance targeting and bioavailability.
Yi Qiu, Shiyuan Huang, Li Peng, Li Yang, Guosong Zhang, Tao Liu, Fang Yan, Xi Peng   +7 more
wiley   +1 more source